Activation of the mechanistic target of rapamycin (mTOR) pathway plays a role in endothelial proliferation and intimal hyperplasia in anti-PL-positive patients, which leads to multiple potential outcomes, including micro thrombosis, peripheral ischemia, skin ulcers, diffuse alveolar hemorrhage, or anti-PL nephropathy. This evidence concerns the gene MTOR and kidney disorder.